Exploring the Immune Response to COVID ‐19 Vaccines in Dialysis and Transplant Patients
Therapeutic Apheresis and Dialysis · 2025
DOI: 10.1111/1744-9987.70066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, 2025. Verfasst von Hui Wen You und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia. Hauptthemen laut MEDLINE: Renal Dialysis, Kidney Transplantation, COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
This study explores immune responses to SARS‐CoV‐2 vaccination among dialysis patients and kidney transplant recipients (KTRs). Dialysis patients and KTRs often exhibit lower seroconversion rates, particularly the latter, due to immunosuppressive therapies.
Methods
The prospective study was conducted at the University Malaya Medical Centre (UMMC), involving 62 dialysis patients and 49 KTRs.
Results
Dialysis patients exhibited high seroconversion (97.8%) and T‐cell response (77.4%). In contrast, KTRs had poor seroconversion (59.2%) and a weak T‐cell response (44.9%) after a third dose. Furthermore, 32.7% of KTRs were non‐reactive in both antibody and T‐cell responses. A moderate correlation was found between antibody levels and T‐cell responses in KTRs ( p = 0.033, r = 0.305). Among dialysis patients, lower BMI was significantly associated with reduced seroconversion, while longer dialysis duration and the presence of hypertension were positively associated with antibody response. Other clinical factors, including age, gender, diabetes, and prior COVID‐19 infection, showed no significant association.
Conclusion
The findings suggest dialysis patients respond better to vaccination, while KTRs experience impaired immune responses. Within dialysis patients, BMI, dialysis duration, and hypertension influenced antibody response. Monitoring post‐vaccination immune responses in KTRs may help identify non‐responders, who could benefit from alternative vaccination strategies or adjustments in immunosuppressive therapy. This study was approved by the University Malaya Medical Centre Medical Research Ethics Committee (UMMC‐MREC), Approval No: 202131‐9888.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia.
- Head of Renal Division University Malaya Medical Center, Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia.
- Department of Molecular Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia.
- Department of Nephrology, Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia.
- Department of Medicine, Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia.
- School of Economics and Management, Xiamen University Malaysia, Sepang, Selangor, Malaysia.
ORCID-Profile: Hui Wei You
Zitieren
APA
You, H. W., Lim, S. K., Kong, B. H., Cheng, S. F., Rajasuriar, R., & You, H. W. (2025). Exploring the Immune Response to COVID ‐19 Vaccines in Dialysis and Transplant Patients. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.70066
Vancouver
You HW, Lim SK, Kong BH, Cheng SF, Rajasuriar R, You HW. Exploring the Immune Response to COVID ‐19 Vaccines in Dialysis and Transplant Patients. Therapeutic Apheresis and Dialysis. 2025. doi:10.1111/1744-9987.70066
BibTeX
@article{You2025,
author = {You, Hui Wen and Lim, Soo Kun and Kong, Boon Hong and Cheng, Shian Feng and Rajasuriar, Reena and You, Hui Wei},
title = {Exploring the Immune Response to COVID ‐19 Vaccines in Dialysis and Transplant Patients},
journal = {Therapeutic Apheresis and Dialysis},
year = {2025},
doi = {10.1111/1744-9987.70066}
}
EUVIMED